Asparaginase products, which are approved for treatment of acute lymphoblastic leukemia (ALL) [7,8,9], but not AML, do not suppress the bone marrow and can provide a treatment option for patients with AML who do not wish to receive blood transfusion [10,11]. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.